A Review on Biomolecular Mechanisms of Parkinsonâ€™s Disease
Degeneration of catecholaminergic (dopamine) neurons in the Substantia Nigra pars compacta of the basal ganglia results in Parkinsonâ€™s disease (PD). The drug of choice is L-dopa, anticholinergics, amantadine, monoamine oxidase-B inhibitors, dopamine agonists, and catechol O-methyl transferase inhibitors are used. Therapeutic strategies are currently managing the symptoms of PD, but not curing the disease. This review draws insights on the molecular mechanisms driving the loss of brain cells in PD.
How to Cite
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.